Compare Cassava Sciences Inc (FLNA) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Lufax Holding Ltd — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Lufax Holding Ltd trades at $0.96 (market cap $982.89M). The key difference: Lufax Holding Ltd is far larger — about 24.9× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 3,323,384). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Lufax Holding Ltd for 13 Days on average.
| FLNA | LU | |
|---|---|---|
Market Cap | $39.40M | $982.89M |
Volume | 759,018 | 3,323,384 |
Sector | Health | Financials |
52-Week High | $4.64 | $3.93 |
52-Week Low | $0.68 | $0.95 |
Typical Hold Time | 37 Days | 13 Days |
Enterprise Value | -$43.28M | $58.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
LU trades at $0.9814, down 2.83% on the day, with a bearish technical signal from moving averages but a bullish signal from oscillators. The company reported a net loss of $2.10 billion on revenue of $23.11 billion in 2025, with negative profit margins and ROE. A 10:1 reverse stock split was implemented on October 23, 2026, and recent news highlights ongoing restructuring and regulatory challenges in China's consumer lending market.
The outlook remains challenging due to persistent losses and revenue declines, but deep value is suggested by a low P/B of 0.07 and significant analyst buy ratings (69%). Key risks include regulatory tightening and liquidity shocks in China, while potential catalysts include balance sheet strength and operational improvements under parent company Ping An's backing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
